A preview of the emerging health companies profiled in the current issue of Start-Up. This month's profile group, "Rare Disease Research: Where Compassion Meets Commerce," features profiles of Afraxis, bluebird bio, Edimer Pharmaceuticals and Ultragenyx Pharmaceutical. Plus these Start-Ups Across Health Care: AirXpanders, Arterion, CortiCare and Sirius Implantable Systems.
The advent of a new set of potential acquirers has heightened
venture capital's interest in rare diseases, resulting in the
creation of a cohort of drug developers that are using cutting edge
technologies to treat and in some cases cure grave illnesses.
Afraxis Inc. is developing p21-activated kinase (PAK) inhibitors, initially for Fragile X syndrome, a genetic condition involving changes in the...
